Joseph Schuermeyer1, Stacy Salomonsen-Sautel1, Rumi Kato Price2, Sundari Balan2, Christian Thurstone3, Sung-Joon Min4, Joseph T Sakai5. 1. Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 2. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States. 3. Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States; Denver Health and Hospital Authority, Denver, Colorado, United States. 4. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 5. Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: joseph.sakai@ucdenver.edu.
Abstract
BACKGROUND: In 2009, policy changes were accompanied by a rapid increase in the number of medical marijuana cardholders in Colorado. Little published epidemiological work has tracked changes in the state around this time. METHODS: Using the National Survey on Drug Use and Health, we tested for temporal changes in marijuana attitudes and marijuana-use-related outcomes in Colorado (2003-11) and differences within-year between Colorado and thirty-four non-medical-marijuana states (NMMS). Using regression analyses, we further tested whether patterns seen in Colorado prior to (2006-8) and during (2009-11) marijuana commercialization differed from patterns in NMMS while controlling for demographics. RESULTS: Within Colorado those reporting "great-risk" to using marijuana 1-2 times/week dropped significantly in all age groups studied between 2007-8 and 2010-11 (e.g. from 45% to 31% among those 26 years and older; p=0.0006). By 2010-11 past-year marijuana abuse/dependence had become more prevalent in Colorado for 12-17 year olds (5% in Colorado, 3% in NMMS; p=0.03) and 18-25 year olds (9% vs. 5%; p=0.02). Regressions demonstrated significantly greater reductions in perceived risk (12-17 year olds, p=0.005; those 26 years and older, p=0.01), and trend for difference in changes in availability among those 26 years and older and marijuana abuse/dependence among 12-17 year olds in Colorado compared to NMMS in more recent years (2009-11 vs. 2006-8). CONCLUSIONS: Our results show that commercialization of marijuana in Colorado has been associated with lower risk perception. Evidence is suggestive for marijuana abuse/dependence. Analyses including subsequent years 2012+ once available, will help determine whether such changes represent momentary vs. sustained effects.
BACKGROUND: In 2009, policy changes were accompanied by a rapid increase in the number of medical marijuana cardholders in Colorado. Little published epidemiological work has tracked changes in the state around this time. METHODS: Using the National Survey on Drug Use and Health, we tested for temporal changes in marijuana attitudes and marijuana-use-related outcomes in Colorado (2003-11) and differences within-year between Colorado and thirty-four non-medical-marijuana states (NMMS). Using regression analyses, we further tested whether patterns seen in Colorado prior to (2006-8) and during (2009-11) marijuana commercialization differed from patterns in NMMS while controlling for demographics. RESULTS: Within Colorado those reporting "great-risk" to using marijuana 1-2 times/week dropped significantly in all age groups studied between 2007-8 and 2010-11 (e.g. from 45% to 31% among those 26 years and older; p=0.0006). By 2010-11 past-year marijuana abuse/dependence had become more prevalent in Colorado for 12-17 year olds (5% in Colorado, 3% in NMMS; p=0.03) and 18-25 year olds (9% vs. 5%; p=0.02). Regressions demonstrated significantly greater reductions in perceived risk (12-17 year olds, p=0.005; those 26 years and older, p=0.01), and trend for difference in changes in availability among those 26 years and older and marijuana abuse/dependence among 12-17 year olds in Colorado compared to NMMS in more recent years (2009-11 vs. 2006-8). CONCLUSIONS: Our results show that commercialization of marijuana in Colorado has been associated with lower risk perception. Evidence is suggestive for marijuana abuse/dependence. Analyses including subsequent years 2012+ once available, will help determine whether such changes represent momentary vs. sustained effects.
Authors: Melanie M Wall; Ernest Poh; Magdalena Cerdá; Katherine M Keyes; Sandro Galea; Deborah S Hasin Journal: Ann Epidemiol Date: 2011-09 Impact factor: 3.797
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Kayla N Tormohlen; Ashley Brooks-Russell; Ming Ma; Kristin E Schneider; Arnold H Levinson; Renee M Johnson Journal: J Stud Alcohol Drugs Date: 2019-01 Impact factor: 2.582
Authors: Jonathan M Davis; Bruce Mendelson; Jay J Berkes; Katie Suleta; Karen F Corsi; Robert E Booth Journal: Am J Prev Med Date: 2015-09-16 Impact factor: 5.043
Authors: Silvia S Martins; Christine M Mauro; Julian Santaella-Tenorio; June H Kim; Magdalena Cerda; Katherine M Keyes; Deborah S Hasin; Sandro Galea; Melanie Wall Journal: Drug Alcohol Depend Date: 2016-10-11 Impact factor: 4.492
Authors: Matthew J Smith; Derin J Cobia; James L Reilly; Jodi M Gilman; Andrea G Roberts; Kathryn I Alpert; Lei Wang; Hans C Breiter; John G Csernansky Journal: Hippocampus Date: 2015-03-11 Impact factor: 3.899
Authors: Rick Kosterman; Jennifer A Bailey; Katarina Guttmannova; Tiffany M Jones; Nicole Eisenberg; Karl G Hill; J David Hawkins Journal: J Adolesc Health Date: 2016-08-11 Impact factor: 5.012
Authors: Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin Journal: Inflamm Bowel Dis Date: 2019-02-21 Impact factor: 5.325